Antiplatelet therapy after drug-eluting stent implantation

Journal of Cardiology

Volumn 65, Issue 2, 2015, Pages 98-104

  Warren, Josephine ^a   Baber, Usman ^a   Mehran, Roxana ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Drug eluting stents; Dual antiplatelet therapy; Percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; PACLITAXEL; RAPAMYCIN; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ANTICOAGULANT THERAPY; DIABETES MELLITUS; DRUG ELUTING STENT; DUAL ANTIPLATELET THERAPY; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; IMPLANTATION; IN-STENT RESTENOSIS; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PHARMACEUTICAL CARE; POSTOPERATIVE COMPLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SECONDARY PREVENTION; STENT THROMBOSIS; TREATMENT DURATION; ADVERSE EFFECTS; DRUG ADMINISTRATION; HEMORRHAGE; MYOCARDIAL ISCHEMIA; PROCEDURES; THROMBOSIS; TIME;

ASPIRIN; DRUG ADMINISTRATION SCHEDULE; DRUG-ELUTING STENTS; HEMORRHAGE; HUMANS; MYOCARDIAL ISCHEMIA; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; SECONDARY PREVENTION; THROMBOSIS; TIME FACTORS;

EID: 84922728984     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2014.10.006     Document Type: Review

References (48)

1. Levine G.N., Bates E.R., Blankenship J.C., Bailey S.R., Bittl J.A., Cercek B., et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011, 124(23):2574-2609.
2. Costa M.A., Simon D.I. Molecular basis of restenosis and drug-eluting stents. Circulation 2005, 111(May (17)):2257-2273. PMID: 15867193 [Epub 2005/05/04.eng].
3. Moses J.W., Leon M.B., Popma J.J., Fitzgerald P.J., Holmes D.R., O'Shaughnessy C., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003, 349(October (14)):1315-1323. PMID: 14523139 [Epub 2003/10/03.eng].
4. Stone G.W., Ellis S.G., Cox D.A., Hermiller J., O'Shaughnessy C., Mann J.T., et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004, 109(April (16)):1942-1947. PMID: 15078803 [Epub 2004/04/14.eng].
5. Baber U., Mehran R., Sharma S.K., Brar S., Yu J., Suh J.-W., et al. Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. J Am Coll Cardiol 2011, 58(October (15)):1569-1577.
6. Stone G.W., Rizvi A., Newman W., Mastali K., Wang J.C., Caputo R., et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010, 362(May (18)):1663-1674. PMID: 20445180 [Epub 2010/05/07.eng].
7. Windecker S., Kolh P., Alfonso F., Collet J.P., Cremer J., Falk V., et al. ESC/EACTS Guidelines of myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with special contribution of the European Association for Percutaneous Cardiovascular Interventions (EAPCI). EuroInterv 2014.
8. Excellence NIfHaC Coronary artery disease - drug-eluting stents. NICE technology appraisal guidance 2008, 152.
9. Lüscher T.F., Steffel J., Eberli F.R., Joner M., Nakazawa G., Tanner F.C., et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 2007, 115(February (8)):1051-1058.
10. Stone G.W., Moses J.W., Ellis S.G., Schofer J., Dawkins K.D., Morice M.C., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007, 356(March (10)):998-1008. PMID: 17296824 [Epub 2007/02/14.eng].
11. Dangas G.D., Claessen B.E., Caixeta A., Sanidas E.A., Mintz G.S., Mehran R. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol 2010, 56(November (23)):1897-1907. PMID: 21109112 [Epub 2010/11/27.eng].
12. Chen M.S., John J.M., Chew D.P., Lee D.S., Ellis S.G., Bhatt D.L. Bare metal stent restenosis is not a benign clinical entity. Am Heart J 2006, 151(6):1260-1264.
13. Stettler C., Wandel S., Allemann S., Kastrati A., Morice M.C., Schomig A., et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007, 370(September (9591)):937-948. PMID: 17869634 [Epub 2007/09/18.eng].
14. Daemen J., Wenaweser P., Tsuchida K., Abrecht L., Vaina S., Morger C., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007, 369(9562):667-678.
15. Palmerini T., Biondi-Zoccai G., Della Riva D., Mariani A., Sabaté M., Smits P.C., et al. Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stentsevidence from a comprehensive network meta-analysis. J Am Coll Cardiol 2014, 63(4):299-307.
16. Bhatt D.L., Fox K.A.A., Hacke W., Berger P.B., Black H.R., Boden W.E., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006, 354(16):1706-1717. PMID: 16531616.
17. Tada T., Natsuaki M., Morimoto T., Furukawa Y., Nakagawa Y., Byrne R.A., et al. Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2. Circ Cardiovasc Interv 2012, 5(June (3)):381-391. PMID: 22619260 [Epub 2012/05/24.eng].
18. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324(January (7329)):71-86. PMID: 11786451. Pubmed Central PMCID: PMC64503 [Epub 2002/01/12.eng].
19. Therapy Coortoa Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994, 308(January (6921)):81-106. PMID: 8298418. Pubmed Central PMCID: PMC2539220 [Epub 1994/01/08.eng].
20. Mehta S.R., Yusuf S., Peters R.J.G., Bertrand M.E., Lewis B.S., Natarajan M.K., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001, 358(9281):527-533.
21. Steinhubl S.R., Berger P.B., Mann J.T., Fry E.T., DeLago A., Wilmer C., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002, 288(November (19)):2411-2420. PMID: 12435254 [Epub 2002/11/19.eng].
22. Gurbel P.A., Bliden K.P., Hiatt B.L., O'Connor C.M. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003, 107(June (23)):2908-2913.
23. Wiviott S.D., Braunwald E., McCabe C.H., Montalescot G., Ruzyllo W., Gottlieb S., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007, 357(20):2001-2015. PMID: 17982182.
24. Wiviott S.D., Braunwald E., Angiolillo D.J., Meisel S., Dalby A.J., Verheugt F.W.A., et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel - Thrombolysis in Myocardial Infarction 38. Circulation 2008, 118(October (16)):1626-1636.
25. Wallentin L., Becker R.C., Budaj A., Cannon C.P., Emanuelsson H., Held C., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009, 361(11):1045-1057. PMID: 19717846.
26. Abbott Vascular Abbott's XIENCE PRIME™ and XIENCE V® drug eluting stents receive indication in Europe for minimum three-month duration of dual anti-platelet therapy: Abbott Vascular May 2012, Available from: http://www-pweb1.abbott.com/news-media/press-releases/abbotts-xience-prime-and-xience-v-drug-eluting-stents-receive-indication-in-europe-for-minimum-th.htm [cited 2014].
27. Schulz S., Schuster T., Mehilli J., Byrne R.A., Ellert J., Massberg S., et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. Eur Heart J 2009, 30(November (22)):2714-2721.
28. Feres F., Costa R.A., Abizaid A., Leon M.B., Marin-Neto J.A., Botelho R.V., et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the optimize randomized trial. JAMA 2013, 310(23):2510-2522.
29. Valgimigli M., Campo G., Monti M., Vranckx P., Percoco G., Tumscitz C., et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 2012, 125(April (16)):2015-2026.
30. Gwon H.C., Hahn J.Y., Park K.W., Song Y.B., Chae I.H., Lim D.S., et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation 2012, 125(January (3)):505-513. PMID: 22179532 [Epub 2011/12/20.eng].
31. Kim B.-K., Hong M.-K., Shin D.-H., Nam C.-M., Kim J.-S., Ko Y.-G., et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol 2012, 60(October (15)):1340-1348.
32. El-Hayek G., Messerli F., Bangalore S., Hong M.K., Herzog E., Benjo A., et al. Meta-analysis of randomized clinical trials comparing short-term versus long-term dual antiplatelet therapy following drug-eluting stents. Am J Cardiol 2014, 114(July (2)):236-242.
33. Cassese S., Byrne R.A., Tada T., King L.A., Kastrati A. Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials. Eur Heart J 2012, 33(December (24)):3078-3087. PMID: 23091199 [Epub 2012/10/24.eng].
34. Park S.J., Park D.W., Kim Y.H., Kang S.J., Lee S.W., Lee C.W., et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 2010, 362(April (15)):1374-1382. PMID: 20231231 [Epub 2010/03/17.eng].
35. Lee C.W., Ahn J.M., Park D.W., Kang S.J., Lee S.W., Kim Y.H., et al. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. Circulation 2014, 129(January (3)):304-312. PMID: 24097439 [Epub 2013/10/08.eng].
36. Mauri L., Kereiakes D.J., Normand S.L., Wiviott S.D., Cohen D.J., Holmes D.R., et al. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J 2010, 160(December (6)):1035-1041. 1041.e1. PMID: 21146655 [Epub 2010/12/15.eng].
37. Helft G., Le Feuvre C., Georges J.L., Carrie D., Leclercq F., Eltchaninoff H., et al. Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial. Trials 2013, 14:56. PMID: 23433461. Pubmed Central PMCID: PMC3598827 [Epub 2013/02/26.eng].
38. Byrne R.A., Schulz S., Mehilli J., Iijima R., Massberg S., Neumann F.J., et al. Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: the Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study. Am Heart J 2009, 157(April (4)). 620-4.e2. PMID: 19332187 [Epub 2009/04/01.eng].
39. Valgimigli M., Borghesi M., Tebaldi M., Vranckx P., Parrinello G., Ferrari R. Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). Eur Heart J 2013, 34(March (12)):909-919. PMID: 23315904 [Epub 2013/01/15.eng].
40. Feres F., Costa R.A., Abizaid A., Leon M.B., Marin-Neto J.A., Botelho R.V., et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 2013, 310(December (23)):2510-2522. PMID: 24177257 [Epub 2013/11/02.eng].
41. Varenhorst C., Jensevik K., Jernberg T., Sundstrom A., Hasvold P., Held C., et al. Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome. Eur Heart J 2014, 35(April (15)):969-978. PMID: 24122961 [Epub 2013/10/15.eng].
42. Iakovou I., Schmidt T., Bonizzoni E., Ge L., Sangiorgi G.M., Stankovic G., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005, 293(17):2126-2130.
43. Armstrong E.J., Rutledge J.C., Rogers J.H. Coronary artery revascularization in patients with diabetes mellitus. Circulation 2013, 128(October (15)):1675-1685. PMID: 24100481. Pubmed Central PMCID: PMC3901842 [Epub 2013/10/09.eng].
44. Brar S.S., Kim J., Brar S.K., Zadegan R., Ree M., Liu I.-L.A., et al. Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions. J Am Coll Cardiol 2008, 51(October (23)):2220-2227.
45. Stone G.W., Kedhi E., Kereiakes D.J., Parise H., Fahy M., Serruys P.W., et al. Differential clinical responses to everolimus-eluting and paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. Circulation 2011, 124(August (8)):893-900. PMID: 21824922 [Epub 2011/08/10.eng].
46. Schoos M.M., Clemmensen P., Dangas G.D. Second-generation drug-eluting stents and bioresorbable vascular scaffolds in patients with diabetes. JACC: Cardiovasc Interv 2014, 7(May (5)):494-496.
47. Ducrocq G., Amarenco P., Labreuche J., Alberts M.J., Mas J.-L., Ohman E.M., et al. A history of stroke/transient ischemic attack indicates high risks of cardiovascular event and hemorrhagic stroke in patients with coronary artery disease. Circulation 2013, 127(February (6)):730-738.
48. Mehran R., Baber U., Steg P.G., Ariti C., Weisz G., Witzenbichler B., et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 2013, 382(9906):1714-1722.